Acinetobacter baumannii: evolution of a global pathogen.

Acinetobacter baumannii is an opportunistic nosocomial pathogen and one of the six most important multidrug-resistant microorganisms in hospitals worldwide. This human pathogen is responsible for a vast array of infections, of which ventilator-associated pneumonia and bloodstream infections are the most common, and mortality rates can reach 35%. Community-acquired infections have also been reported, but few strains have been recovered from environmental sources and infection reservoirs external to the hospital have not been identified. The majority of A. baumannii infections are caused by two main population clones with worldwide distribution. Infection outbreaks are often associated with multidrug resistance, including the recent emergence of strains resistant to all available antibiotics. Nevertheless, A. baumannii virulence traits and pathogenic potential have mostly remained elusive. The recent expansion of A. baumannii sequenced genomes has permitted the development of large-array phylogenomic and phenotypic analyses, which can offer valuable insights into the evolution and adaptation of A. baumannii as a human pathogen. This review summarises these recent advances, with particular focus on A. baumannii evolutionary and genomic aspects, and proposes new avenues of research.

[1]  H. Seifert,et al.  Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Nichollas E. Scott,et al.  Identification of a General O-linked Protein Glycosylation System in Acinetobacter baumannii and Its Role in Virulence and Biofilm Formation , 2012, PLoS pathogens.

[3]  M. Joly-Guillou,et al.  Clinical impact and pathogenicity of Acinetobacter. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  A. Koster,et al.  Do Biofilm Formation and Interactions with Human Cells Explain the Clinical Success of Acinetobacter baumannii? , 2010, PloS one.

[5]  M. Adams,et al.  The Success of Acinetobacter Species; Genetic, Metabolic and Virulence Attributes , 2012, PloS one.

[6]  Eric P. Skaar,et al.  Inactivation of Phospholipase D Diminishes Acinetobacter baumannii Pathogenesis , 2010, Infection and Immunity.

[7]  M. Adams,et al.  Comparative Genome Sequence Analysis of Multidrug-Resistant Acinetobacter baumannii , 2008, Journal of bacteriology.

[8]  Mark J. Pallen,et al.  Bacterial pathogenomics , 2007, Nature.

[9]  P. Visca,et al.  Genome-assisted identification of putative iron-utilization genes in Acinetobacter baumannii and their distribution among a genotypically diverse collection of clinical isolates. , 2011, Research in microbiology.

[10]  L. Actis,et al.  Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. , 2003, Microbiology.

[11]  R. Bonomo,et al.  Isolation and Characterization of an Autoinducer Synthase from Acinetobacter baumannii , 2008, Journal of bacteriology.

[12]  F. Fang,et al.  New insights into transcriptional regulation by H-NS. , 2008, Current opinion in microbiology.

[13]  Paul Keim,et al.  Evolution of a Pathogen: A Comparative Genomics Analysis Identifies a Genetic Pathway to Pathogenesis in Acinetobacter , 2013, PloS one.

[14]  Chul Hee Choi,et al.  Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells , 2005, Cellular microbiology.

[15]  I. Rasooli,et al.  Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). , 2011, Microbial pathogenesis.

[16]  Qiyu Bao,et al.  Bioinformatic analysis of the Acinetobacter baumannii phage AB1 genome. , 2012, Gene.

[17]  A. Tayabali,et al.  Comparison of the Virulence Potential of Acinetobacter Strains from Clinical and Environmental Sources , 2012, PloS one.

[18]  M. Kempf,et al.  The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. , 2010, The Journal of infection.

[19]  M. Falagas,et al.  Nephrotoxicity of colistin: new insight into an old antibiotic. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Hall,et al.  Variation in the Complex Carbohydrate Biosynthesis Loci of Acinetobacter baumannii Genomes , 2013, PloS one.

[21]  A. Sundsfjord,et al.  Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[22]  L. Dijkshoorn,et al.  The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool , 2010, PloS one.

[23]  J. Gaddy,et al.  Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. , 2008, Microbiology.

[24]  L. Dijkshoorn,et al.  Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. , 2006, Research in microbiology.

[25]  W. Lu,et al.  Comparative analysis of the complete genome of an Acinetobacter calcoaceticus strain adapted to a phenol-polluted environment. , 2012, Research in microbiology.

[26]  T. Umland,et al.  The K1 Capsular Polysaccharide of Acinetobacter baumannii Strain 307-0294 Is a Major Virulence Factor , 2010, Infection and Immunity.

[27]  J. Gaddy,et al.  Role of Acinetobactin-Mediated Iron Acquisition Functions in the Interaction of Acinetobacter baumannii Strain ATCC 19606T with Human Lung Epithelial Cells, Galleria mellonella Caterpillars, and Mice , 2012, Infection and Immunity.

[28]  R. Lal,et al.  Genome Sequence of Acinetobacter sp. Strain HA, Isolated from the Gut of the Polyphagous Insect Pest Helicoverpa armigera , 2012, Journal of bacteriology.

[29]  Mark Gerstein,et al.  New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. , 2007, Genes & development.

[30]  N. Loman,et al.  Defining bacterial species in the genomic era: insights from the genus Acinetobacter , 2012, BMC Microbiology.

[31]  M. McConnell,et al.  Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. , 2013, FEMS microbiology reviews.

[32]  Matteo Brilli,et al.  Exploring the evolutionary dynamics of plasmids: the Acinetobacter pan-plasmidome , 2010, BMC Evolutionary Biology.

[33]  Karl A. Hassan,et al.  H-NS Plays a Role in Expression of Acinetobacter baumannii Virulence Features , 2013, Infection and Immunity.

[34]  K. Towner Acinetobacter: an old friend, but a new enemy. , 2009, The Journal of hospital infection.

[35]  M. Hilty,et al.  Extended-spectrum cephalosporin-resistant Gram-negative organisms in livestock: an emerging problem for human health? , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[36]  V. Rotimi,et al.  Emergence of Tigecycline and Colistin Resistance in Acinetobacter Species Isolated from Patients in Kuwait Hospitals , 2011, Journal of chemotherapy.

[37]  J. Bartlett,et al.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  S. Amyes,et al.  The rise of carbapenem-resistant Acinetobacter baumannii. , 2012, Current pharmaceutical design.

[39]  J. Gaughan,et al.  Morphine, but Not Trauma, Sensitizes to Systemic Acinetobacter baumannii Infection , 2011, Journal of Neuroimmune Pharmacology.

[40]  P. Visca,et al.  Deciphering the Multifactorial Nature of Acinetobacter baumannii Pathogenicity , 2011, PloS one.

[41]  J. Lawrence,et al.  Common themes in the genome strategies of pathogens. , 2005, Current opinion in genetics & development.

[42]  B. Berçot,et al.  Carbapenemase-producing Acinetobacter spp. in Cattle, France , 2012, Emerging infectious diseases.

[43]  P. Nordmann,et al.  Genetic basis of antibiotic resistance in pathogenic Acinetobacter species , 2011, IUBMB life.

[44]  G. Pier,et al.  Poly-N-Acetyl-β-(1-6)-Glucosamine Is a Target for Protective Immunity against Acinetobacter baumannii Infections , 2011, Infection and Immunity.

[45]  Y. Chuang,et al.  Community-Acquired Acinetobacter Meningitis in Adults , 2000, Infection.

[46]  M. Triassi,et al.  Genome organization of epidemic Acinetobacter baumannii strains , 2011, BMC Microbiology.

[47]  L. Dijkshoorn,et al.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.

[48]  J. Poulain,et al.  Comparative Analysis of Acinetobacters: Three Genomes for Three Lifestyles , 2008, PloS one.

[49]  M. Iacono,et al.  The genomics of Acinetobacter baumannii: Insights into genome plasticity, antimicrobial resistance and pathogenicity , 2011, IUBMB life.

[50]  D. Hospenthal,et al.  Changes in the Incidences of Multidrug-Resistant and Extensively Drug-Resistant Organisms Isolated in a Military Medical Center , 2010, Infection Control & Hospital Epidemiology.

[51]  J. Vila,et al.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace , 2012, Front. Microbio..

[52]  R. Fani,et al.  The genome sequence of the hydrocarbon-degrading Acinetobacter venetianus VE-C3. , 2013, Research in microbiology.

[53]  P. Nordmann,et al.  First Isolation of the blaOXA-23 Carbapenemase Gene from an Environmental Acinetobacter baumannii Isolate , 2009, Antimicrobial Agents and Chemotherapy.

[54]  Nichollas E. Scott,et al.  A common pathway for O‐linked protein‐glycosylation and synthesis of capsule in Acinetobacter baumannii , 2013, Molecular microbiology.

[55]  Patrick A. D. Grimont,et al.  Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii , 1986 .

[56]  Kerri A. Thom,et al.  Genomic comparison of multi-drug resistant invasive and colonizing Acinetobacter baumannii isolated from diverse human body sites reveals genomic plasticity , 2011, BMC Genomics.

[57]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.

[58]  Karl A. Hassan,et al.  The Complete Genome and Phenome of a Community-Acquired Acinetobacter baumannii , 2013, PloS one.

[59]  L. Dijkshoorn,et al.  Multidrug-Resistant , 2021, Encyclopedia of Molecular Pharmacology.

[60]  D. Raoult,et al.  Acinetobacter baumannii in Human Body Louse , 2004, Emerging infectious diseases.

[61]  Michele Iacono,et al.  Whole-Genome Pyrosequencing of an Epidemic Multidrug-Resistant Acinetobacter baumannii Strain Belonging to the European Clone II Group , 2008, Antimicrobial Agents and Chemotherapy.

[62]  B. M. Hansen,et al.  The hidden lifestyles of Bacillus cereus and relatives. , 2003, Environmental microbiology.

[63]  M. Adams,et al.  Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis , 2012, mBio.

[64]  K. Sayood,et al.  Characterization of the Acinetobacter baumannii growth phase-dependent and serum responsive transcriptomes. , 2012, FEMS immunology and medical microbiology.

[65]  F. Leighton Pathogens and Disease , 2002 .

[66]  J. Malone,et al.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. , 2004, MMWR. Morbidity and mortality weekly report.

[67]  M. Falagas,et al.  Attributable mortality of Acinetobacter baumannii: no longer a controversial issue , 2007, Critical care.

[68]  R. Mera,et al.  Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. , 2010, Microbial drug resistance.

[69]  Rui Wang,et al.  Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. , 2012, The Journal of antimicrobial chemotherapy.

[70]  L. Dijkshoorn,et al.  Differences in Acinetobacter baumannii Strains and Host Innate Immune Response Determine Morbidity and Mortality in Experimental Pneumonia , 2012, PloS one.

[71]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[72]  T. Umland,et al.  Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. , 2009, The Journal of infectious diseases.

[73]  T. Kelesidis,et al.  Community-acquired Acinetobacter infections , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[74]  Karl A. Hassan,et al.  Adherence and motility characteristics of clinical Acinetobacter baumannii isolates. , 2011, FEMS microbiology letters.

[75]  P. Visca,et al.  Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78 , 2013, BMC Infectious Diseases.

[76]  G. Pier,et al.  Identification of Ata, a Multifunctional Trimeric Autotransporter of Acinetobacter baumannii , 2012, Journal of bacteriology.

[77]  Eric P. Skaar,et al.  Host–microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection , 2012, Cellular microbiology.

[78]  J. Rolain,et al.  Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. , 2012, International journal of antimicrobial agents.

[79]  Laura Camarena,et al.  Molecular Mechanisms of Ethanol-Induced Pathogenesis Revealed by RNA-Sequencing , 2010, PLoS pathogens.

[80]  J. Bartlett,et al.  Erratum: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America (Clinical Infectious Diseases (March 1, 2006) 42 (657-668)) , 2006 .

[81]  M. Kempf,et al.  Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.